Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01327781
First received: March 31, 2011
Last updated: July 30, 2014
Last verified: July 2014
  Purpose

This phase I trial studies the side effects and the best dose of Z-endoxifen hydrochloride in treating patients with metastatic or locally recurrent estrogen receptor-positive (ER+) breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using Z-endoxifen hydrochloride may fight breast cancer by blocking the use of estrogen by tumor cells.


Condition Intervention Phase
Estrogen Receptor-positive Breast Cancer
Hot Flashes
Recurrent Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Drug: Z-endoxifen hydrochloride
Other: questionnaire administration
Other: pharmacological study
Other: laboratory biomarker analysis
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • MTD defined as the highest dose level where at most 1 of 6 patients develops a dose limiting toxicity and 2 or more of the 3-6 patients treated at the next higher dose level develop a dose limiting toxicity [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The maximum grade of each type of toxicity will be recorded for each patient. For each toxicity reported by dose level, the percentage of patients developing any degree of that toxicity as well as the percentage of patients developing a severe degree (grade 3 or higher) will be determined.


Secondary Outcome Measures:
  • Progression-free survival [ Time Frame: From study entry to the documentation of disease progression, assessed up to 30 days ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: From study entry to death due to any cause, assessed up to 30 days ] [ Designated as safety issue: No ]
  • Change in hot flash scores graded using a hot flash diary and the hot flash interference scale [ Time Frame: Baseline to day 28 ] [ Designated as safety issue: No ]
    The number and severity of hot flashes will be examined. Times series plots of hot flash scores will be constructed to visually assess changes across time within a dose level and between dose levels. In particular, for each expansion dose level, a 90% confidence interval will be constructed for the proportion of patients whose hot flash scores increase at least 2 fold from baseline after one course of treatment.


Other Outcome Measures:
  • Tumor expression levels of SRC3 [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of SRC1 [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of IGF1R [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of PI3K [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of AKT [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of mTOR [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of phosphorylated ribosomal protein S6 kinase kinase [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of epidermal growth factor receptor [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of HER2 [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of p42/p44 mitogen-activated protein kinase [ Time Frame: Baseline up to day 28 ] [ Designated as safety issue: No ]
    A grid (similar to a heat map) will be constructed where columns represent the proteins and the rows represent individual patients. This grid will be visual inspected for differences between expansion dose levels as well as tendencies of protein level shifts than seem to behave similarly.

  • Tumor expression levels of Ki-67 [ Time Frame: Baseline up to day 56 ] [ Designated as safety issue: No ]
    For Ki-67 by expansion dose level, a 90% binomial confidence interval for the mean change in the percentage of positive cells after 2 courses of treatment from pre-Z-endoxifen treatment levels will be determined. Also, Spearman rank correlation coefficients will be used to examine the strength of the association between the change in ER positivity, PR positivity, and Ki-67 positivity.


Estimated Enrollment: 42
Study Start Date: March 2011
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (Z-endoxifen hydrochloride)
Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Z-endoxifen hydrochloride
Given PO
Other Names:
  • (Z)-endoxifen
  • Z-endoxifen HCl
Other: questionnaire administration
Ancillary studies
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:

PRIMARY OBJECTIVES:

l. To determine either the maximum-tolerated dose (MTD) of Z-endoxifen hydrochloride or the dose level associated with endoxifen steady state concentration (Css) of at least 2 uM in women with metastatic estrogen-receptor positive (ER+) breast cancer.

II. To describe the safety profile of Z-endoxifen (Z-endoxifen hydrochloride) at each of the doses examined.

III. To evaluate changes in vision after 2 cycles of treatment. IV. To gather preliminary data on the clinical benefit in terms of tumor response rate and progression-free survival.

V. To evaluate the changes in the frequency and severity of hot flashes after 2 cycles of treatment (Expansion cohort).

VI. Evaluate changes in irritability scale using a validated Irritability questionnaire (Expansion cohort).

VII. To evaluate changes in markers of bone formation and absorption after 2 cycles of treatment (Expansion cohort).

XIII. To evaluate changes in vision after 2 cycles of treatment (Expansion cohort).

IX. To further characterize the safety profile of Z-endoxifen hydrochloride (Expansion cohort).

SECONDARY OBJECTIVES:

I. To characterize the plasma pharmacokinetics and urinary excretion of Z-endoxifen hydrochloride at each of the doses examined.

II. For patients beginning in dose level 7 as well as the expansion cohorts, we will describe any changes in tumor expression of ER (both full length and truncated forms), progesterone receptor (PR), steroid receptor co-activator (SRC)1, SRC3, as well as the insulin-like growth factor receptor (IGF)1R/phosphatidylinositol 3 kinase (PI3K)/v-akt Murine Thymoma Viral Oncogene Homolog 1 (AKT)/mammalian target of rapamycin (mTOR) pathway and proliferation-related Ki-67 antigen (Ki67) after 1 cycle of treatment (approximately 28 days).

III. To determine the frequency of estrogen receptor 1 (ESR1) mutations and the presence of antitumor activity (response rate and progression free survival [PFS]) in all patients whose tumors harbor ESR1 alterations.

IV. To determine whether the ESR1 mutations identified in pre-treatment tumor biopsies can be detected in matched plasma cell free deoxyribonucleic acid (DNA) from the same patients.

OUTLINE: This is a dose-escalation study followed by an expansion cohort study.

Patients receive Z-endoxifen hydrochloride orally (PO) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up for 30 days.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of metastatic or locally recurrent breast cancer
  • ER positive defined as > 1% nuclear staining on the biopsy that was obtained at the confirmation of metastatic or locally recurrent disease
  • Lesion type:

Either evaluable or measurable disease

  • Pre- or post-menopausal female
  • For the expansion cohorts: tumor that is accessible for biopsy
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Life expectancy > 16 weeks
  • Capable of understanding investigational nature, potential risks and benefits of the study and able to provide written informed consent
  • Absolute neutrophil count (ANC) >= 1,000/μL
  • Platelet count >= 75,000/μL
  • Total bilirubin =< 1.5 times institutional upper limit of normal (IULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times IULN (< 5 times IULN if liver function test [LFT] elevations due to liver metastases)
  • Creatinine =< 1.5 times IULN
  • Women with human epidermal growth factor (HER)-2 positive disease must have received and progressed on at least one prior anti-HER-2 directed regimen (trastuzumab, lapatinib) for their metastatic disease

    • For dose escalation cohort:

      • Any number of prior systematic therapy regimens is allowed

        • NOTE: prior systematic therapy in the adjuvant setting is not required
      • At least one prior hormone containing regimen in the metastatic setting (tamoxifen if pre-menopausal; aromatase inhibitor if post-menopausal)

        • NOTE: exception: patients that fail (defined as the development of metastatic disease while receiving an adjuvant hormone containing regimen of tamoxifen for premenopausal and aromatase inhibitor for postmenopausal) are eligible and not required to receive additional hormonal containing regimens prior to enrollment
      • At least one prior chemotherapy containing regimen in adjuvant and/or metastatic setting
    • For the expansion cohort(s):

      • At least one prior hormone containing regimen in the metastatic setting (tamoxifen if pre-menopausal; aromatase inhibitor if post-menopausal)

        • NOTE: exception: patients that fail (defined as the development of metastatic disease while receiving an adjuvant hormone containing regimen of tamoxifen for premenopausal and aromatase inhibitor for postmenopausal) are eligible and not required to receive additional hormonal containing regimens prior to enrollment
      • NOTE: a prior hormone containing regimen in the adjuvant setting is not required; a hormonal regimen containing everolimus is allowed
      • Either 1 or 2 prior chemotherapy regimens are allowed but not required such that both are in the metastatic setting or one is in the adjuvant setting and one in the metastatic setting (note, an anthracycline and taxane based regimen delivered in the adjuvant setting would be considered one regimen)
  • Willingness to return to Mayo Clinic Rochester, Arizona, or Florida during treatment phase of the trial
  • Dose Escalation cohort only:

    • Mandatory Translational Research Components

      • Willingness to provide biologic specimens (blood and urine)
    • Dose Escalation cohorts beginning at 160 mg/day: Mandatory Translational Research Components

      • Willingness to provide biologic specimens (tissue)
    • Dose Expansion cohort(s):

      • Mandatory Translational Research Components

        • Willingness to provide biologic specimens (blood, tissue and urine)
      • Note: The goals of this study include assessment of the biologic effects on surrogate markers of Z-endoxifen and therefore, are contingent upon availability of the biologic specimens
  • Women of childbearing potential only: negative serum pregnancy test done =< 48 hours prior to registration
  • Capable of swallowing 20-mg capsules

Exclusion Criteria:

  • Any of the following therapies prior to registration:

    • Chemotherapy =< 3 weeks
    • Immunotherapy =< 3 weeks
    • Biologic therapy =< 3 weeks
    • Hormonal therapy =< 3 weeks
    • Monoclonal antibodies =< 3 weeks
    • Radiation therapy =< 3 weeks
    • Anti-Her-2 directed therapy =< 3 weeks
  • Prior endoxifen therapy
  • Prior history of:

    • Stroke =< 6 months prior to registration
    • Seizures =< 3 months prior to registration
    • Deep vein thrombosis (DVT) or pulmonary embolism (PE) =< 12 months prior to registration
    • Two or more episodes of DVT and/or PE =< 5 years prior to registration
    • Crystalline retinopathy
    • Abnormal uterine bleeding =< 1 year prior to registration
  • Personal history of coagulopathy
  • Active DVT and/or PE requiring anti-coagulant therapy

    • Patients who are on anti-coagulant therapy for maintenance are eligible as long as the DVT and/or PE was > 12 months prior to enrollment and there is no evidence for active thrombosis (either DVT or PE)
  • Clinically symptomatic cataracts requiring imminent surgery

    • Patients that have cataracts that do not require surgery are eligible
  • Other invasive malignancy that has been diagnosed or has recurred < 2 years prior to registration except non-melanotic skin cancer or carcinoma-in-situ of the cervix
  • Any co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situations that would limit compliance with study requirements
  • Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment; EXCEPTION: Neuropathies - if grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment patient is eligible
  • Tumors involving the spinal cord or heart Note: tamoxifen has known estrogenic side-effects; while Z-endoxifen is considered a potent anti-estrogen and is not known to have estrogenic or agonist effects in vitro, the effect of Z-endoxifen in humans is unknown
  • Uncontrolled brain metastases Note: Brain metastases are not permitted on study unless the metastases have been treated by surgery or radiotherapy, and the patient has been neurologically stable and off steroids for >= 12 weeks
  • Plans to begin bisphosphonates or denosumab after registration or began a bisphosphonate or denosumab regimen < 90 days before registration Note: Patients on a stable dose of bisphosphonates or denosumab for > 90 days prior to registration are eligible
  • Any of the following:

    • Pregnant women
    • Nursing women
    • Women of childbearing potential who are unwilling to employ adequate contraception
  • Other concurrent chemotherapy or anti HER2 therapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01327781

Locations
United States, Arizona
Mayo Clinic in Arizona Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Donald W. Northfelt    507-538-7623    Northfelt.Donald@mayo.edu   
Principal Investigator: Donald W. Northfelt         
United States, Florida
Mayo Clinic in Florida Recruiting
Jacksonville, Florida, United States, 32224-9980
Contact: Michael E. Menefee    507-538-7623    menefee.michael@mayo.edu   
Principal Investigator: Michael E. Menefee         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Matthew P. Goetz    507-284-2511    goetz.matthew@mayo.edu   
Principal Investigator: Matthew P. Goetz         
Sponsors and Collaborators
Investigators
Principal Investigator: Matthew Goetz Mayo Clinic
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01327781     History of Changes
Other Study ID Numbers: NCI-2011-00847, NCI-2011-00847, CDR0000696902, MC093C, 8821, P30CA015083, UM1CA186686, U01CA069912
Study First Received: March 31, 2011
Last Updated: July 30, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Hot Flashes
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 26, 2014